Nivolumab / Relatlimab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
DMC (Denmark), PBAC (Australia) and SMC (Scotland) recommended or restricted nivolumab / relatlimab, while AOTMIT (Poland), HAS (France) and ZIN (Netherlands) did not recommend it.
Every record falls within a 1.8-year window, 2023 to 21 May 2025 — a compressed review cycle.
No assessment is on file from PHARMAC (New Zealand), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 8 of 8 records date from 2023 or later.
3 distinct indication wordings are recorded for nivolumab / relatlimab by the agencies that label one in English (AWMSG, PBAC and SMC).
2 of these 8 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess nivolumab / relatlimab, in 2023; DMC (Denmark) did not open a file until 21 May 2025 — a moderate spread of 1.8 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 4 of 8 dated records fall in 2024 alone.
PBAC (Australia) is the only agency to have returned to nivolumab / relatlimab, recording 2 separate entries.
7 of the 18 agencies in this archive hold a record for nivolumab / relatlimab.
The full ledger for nivolumab / relatlimab reads 4 recommended, 3 not recommended and 1 deferred to NICE.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| DMC (Denmark) | 21 May 2025 | Ikke-rekterbar eller metastatisk melanom | Anbefalet | source |
| SMC (Scotland) | 8 Jul 2024 | For treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and over. | accepted | source |
| ZIN (Netherlands) | 23 May 2024 | Advies - niet vergoeden nivolumab-relatlimab (Opdualag®) voor de behandeling van huidkanker | not reimbursed (sluis) | source |
| HAS (France) | 10 Jan 2024 | Listing (Transparency Committee) | SMR insufficient · ASMR IV | source |
| AWMSG (Wales) | 3 Jan 2024 | Untreated unresectable or metastatic melanoma | excluded, NICE appraised | source |
3 further decisions for nivolumab / relatlimab, across 2 agencies, are not shown here. They link to 2 further source documents.
Related molecules
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
- blinatumomab — same ATC class L01F — Antineoplastics
Coverage: 8 decisions for nivolumab / relatlimab from 7 agencies, 2023 to 2025. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.